| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -25,650 | -18,350 | -19,690 | -14,270 | -10,040 |
| Net Income Growth | -39.78% | +6.81% | -37.98% | -42.13% | +34.38% |
Theriva Biologics Inc (TOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Theriva Biologics Inc. is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company's lead candidate includes VCN-01, SYN-004 and SYN-020. Theriva Biologics Inc., formerly known as Synthetic Biologics Inc., is based in ROCKVILLE, Md.
Fiscal Year End Date: 12/31